Highest-materiality recent filing
Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review
Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.
Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review
Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.
CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.
Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M
Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.
Fulcrum reports ~$352.3M cash as of Dec 31, 2025; updates presentation for JPM conference
Preliminary unaudited cash, cash equivalents and marketable securities of $352.3M as of December 31, 2025.
Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants
Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.
Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.
Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end
Cash, equivalents and marketable securities $200.6M; cash runway into 2028.
Company made an updated corporate presentation available on its website for investor meetings.
Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD
Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.
Fulcrum Therapeutics 2025 annual meeting passes director elections, say-on-pay, auditor ratification
Class III directors Katina Dorton, Robert Gould, and Kate Haviland elected with 44.6M, 43.8M, and 33.2M votes for, respectively.
Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated
Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.
MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties
MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.
Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027
Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.
Fulcrum expects ~$240M cash at year-end 2024 (preliminary)
Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).
Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones
Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.
Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing
Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.
Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics
James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.
Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings
Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.
Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended
REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.
RA Capital exchanged 8,500,000 shares for a pre-funded warrant for 8,500,000 shares at $0.001 exercise price, no expiration.
Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024
Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.
Fulcrum expands board to 9, elects Colin Hill; stockholders elect directors, ratify auditor
Board expanded from 8 to 9; Colin Hill elected Class I director, term expiring at 2026 annual meeting.
Fulcrum signs $80M upfront Sanofi deal for losmapimod ex-U.S.; Q1 net loss $26.9M
Sanofi pays $80M upfront; Fulcrum eligible for up to $975M in milestones and tiered low-teens to mid-twenties royalties on ex-U.S. sales.
On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.
On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.
elected Colin Hill as a member of the Board, effective June 17, 2024
Max materiality 0.90 · Median 0.68 · Most common event other_material